Most Recent

image: Opinion: GMOs Are Not “Frankenfoods”

Opinion: GMOs Are Not “Frankenfoods”

By and | August 30, 2016

It behooves the scientific community to reflect on the public’s “Franken-” characterization of genetically modified foods.

9 Comments

image: Opinion: Engineering the Epigenome

Opinion: Engineering the Epigenome

By , and | August 26, 2015

The use of targetable chromatin modifiers has ushered in a new era of functional epigenomics.

1 Comment

image: Opinion: Share Diverse Genomic Data

Opinion: Share Diverse Genomic Data

By | August 12, 2015

Personalized interpretation is the next frontier in clinical genomics, but we won’t get there without sharing data representing all ethnic groups.

0 Comments

image: Opinion: Too Many Mitochondrial Genome Papers

Opinion: Too Many Mitochondrial Genome Papers

By | June 29, 2015

And too few insights gleaned from them

4 Comments

image: Opinion: How Postdocs Can Participate

Opinion: How Postdocs Can Participate

By | September 18, 2014

Graduate students and postdoctoral researchers should be taking part in discussions on the future of biomedical research.

6 Comments

image: Opinion: Bioinformatics Software: A Buyer’s Guide

Opinion: Bioinformatics Software: A Buyer’s Guide

By | September 2, 2014

How to choose programs that suit your lab’s ’omics analysis needs

0 Comments

image: Opinion: GM Salmon: Just the Beginning

Opinion: GM Salmon: Just the Beginning

By | June 1, 2014

Sound risk management concerning genetically engineered food animals is critical. 

2 Comments

image: Opinion: Sizing Up GM Salmon

Opinion: Sizing Up GM Salmon

By | June 1, 2014

On the potential benefits and risks of genetically modified fish entering the marketplace 

0 Comments

image: Opinion: The Pitfalls of Uncertainty

Opinion: The Pitfalls of Uncertainty

By | April 14, 2014

How to successfully inform policy when scientific evidence is not plainly evident.

2 Comments

image: Opinion: Overcoming Cancer’s Complexities

Opinion: Overcoming Cancer’s Complexities

By , and | April 11, 2014

Considering “targeted therapeutics” in the face of intra-patient heterogeneity. 

2 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech